AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo

30 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)

10 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

06 Jun 2022 08:30:00 By Nasdaq GlobeNewswire

Amarin Appoints Tom Reilly as New Chief Financial Officer

06 Jun 2022 08:15:00 By Nasdaq GlobeNewswire

Amarin Announces Appointment of New Directors and Board Leadership Changes

19 May 2022 08:23:13 By Nasdaq GlobeNewswire

Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

16 May 2022 08:00:01 By Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

12 May 2022 08:00:01 By Nasdaq GlobeNewswire

Amarin Reports First Quarter 2022 Financial Results and Provides Business Update

04 May 2022 07:00:01 By Nasdaq GlobeNewswire

New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)

03 May 2022 08:00:02 By Nasdaq GlobeNewswire

Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)

26 Apr 2022 08:49:33 By Nasdaq GlobeNewswire

Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022

19 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes

01 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Amarin Receives Reimbursement for VAZKEPA® in Sweden

28 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific Session

21 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention

10 Mar 2022 08:47:44 By Nasdaq GlobeNewswire

Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

01 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin to Participate in Cowen 42nd Annual Health Care Conference

25 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level

24 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

15 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

10 Jan 2022 07:00:04 By Nasdaq GlobeNewswire